- CA$43.32m
- CA$66.25m
- CA$17.75m
- 13
- 52
- 36
- 24
Annual cashflow statement for LSL Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2012 July 31st | 2021 July 31st | 2022 July 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 15 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.83 | -0.091 | -0.074 | -8.47 | 3.32 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.48 | — | — | 5.01 | -2.54 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.078 | 0.016 | 0.071 | -4.74 | -3.98 |
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.32 | -0.075 | -0.003 | -7.07 | -1.65 |
| Capital Expenditures | -0.528 | — | — | -1.02 | -2.68 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.055 | — | — | — | -4.78 |
| Acquisition of Business | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.473 | — | — | -1.02 | -7.46 |
| Financing Cash Flow Items | -0.119 | 0.065 | 0.004 | -2.83 | -2.29 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.874 | 0.065 | 0.004 | 8.1 | 9.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.081 | -0.01 | 0 | 0.008 | 0.288 |